Shattuck Labs
About
Overview
Our Origins
Mission & Vision
Management
Board of Directors
Advisory Board
Our Science
ARC Platform
GADLEN Platform
Posters
Publications
Pipeline
Clinical
SL-172154
SIRPα-Fc-CD40L
SL-279252
PD1-Fc-OX40L
Discovery
Clinical Trials
Overview
SL-172154
SIRPα-Fc-CD40L
SL-279252
PD1-Fc-OX40L
Investors
Overview
News & Events
Press Releases
Events & Presentations
Stock Info
Stock Quote & Chart
Financials
SEC Filings
Quarterly Results
Governance
Documents & Charters
Management Team
Board of Directors
Committee Composition
IR Resources
FAQS
Email Alerts
IR & Media Contact
Careers
Intro to Shattuck
Values
Benefits
Join Our Team
Current Openings
Contact
Locations
Contact Us
Our Science
Our Science
About
Overview
Our Origins
Mission & Vision
Management
Board of Directors
Advisory Board
Our Science
ARC Platform
GADLEN Platform
Posters
Publications
Pipeline
Clinical
SL-172154
SIRPα-Fc-CD40L
SL-279252
PD1-Fc-OX40L
Discovery
Clinical Trials
Overview
SL-172154
SIRPα-Fc-CD40L
SL-279252
PD1-Fc-OX40L
Investors
Overview
News & Events
Press Releases
Events & Presentations
Stock Info
Stock Quote & Chart
Financials
SEC Filings
Quarterly Results
Governance
Documents & Charters
Management Team
Board of Directors
Committee Composition
IR Resources
FAQS
Email Alerts
IR & Media Contact
Careers
Intro to Shattuck
Values
Benefits
Join Our Team
Current Openings
Contact
Locations
Contact Us
Posters
Year
All
2019
SITC 2019
November 11, 2019
An engineered bi-functional fusion protein (CD86-Fc-NKG2a) to reverse NK cell tolerance of malignant cells
SITC 2019
November 11, 2019
Co-Stimulation of OX40 or LTβ Reprogams Exhausted Lymphocytes to Acquire an Effector Phenotype in the Setting of Combined TIGIT and Checkpoint Blockade
SITC 2018
January 25, 2019
Agonist Redirected Checkpoint Platform (ARC); Engineering Bi-Functional Fusion Proteins (PD1-FC-OX40L), For Cancer Immunotherapy
SITC 2018
January 25, 2019
Agonist Redirected Checkpoint Platform (ARC); Engineering Bi-Functional Fusion Proteins (SIRPα-Fc-CD40L), for Cancer Immunotherapy
SITC 2018
January 2, 2019
Agonist Redirected Checkpoint Platform (ARC); Engineering Bi-Functional Fusion Proteins (TIM3-Fc-OX40L and TIM3-Fc-CD40L), for Cancer Immunotherapy
SITC 2019
November 11, 2019
An engineered bi-functional fusion protein (CD86-Fc-NKG2a) to reverse NK cell tolerance of malignant cells
SITC 2019
November 11, 2019
Co-Stimulation of OX40 or LTβ Reprogams Exhausted Lymphocytes to Acquire an Effector Phenotype in the Setting of Combined TIGIT and Checkpoint Blockade
SITC 2018
January 25, 2019
Agonist Redirected Checkpoint Platform (ARC); Engineering Bi-Functional Fusion Proteins (PD1-FC-OX40L), For Cancer Immunotherapy
SITC 2018
January 25, 2019
Agonist Redirected Checkpoint Platform (ARC); Engineering Bi-Functional Fusion Proteins (SIRPα-Fc-CD40L), for Cancer Immunotherapy
SITC 2018
January 2, 2019
Agonist Redirected Checkpoint Platform (ARC); Engineering Bi-Functional Fusion Proteins (TIM3-Fc-OX40L and TIM3-Fc-CD40L), for Cancer Immunotherapy
About
Overview
Our Origins
Mission & Vision
Management
Board of Directors
Advisory Board
Our Science
ARC Platform
GADLEN Platform
Posters
Publications
Pipeline
Clinical
SL-172154
SIRPα-Fc-CD40L
SL-279252
PD1-Fc-OX40L
Discovery
Clinical Trials
Overview
SL-172154
SIRPα-Fc-CD40L
SL-279252
PD1-Fc-OX40L
Investors
Overview
News & Events
Press Releases
Events & Presentations
Stock Info
Stock Quote & Chart
Financials
SEC Filings
Quarterly Results
Governance
Documents & Charters
Management Team
Board of Directors
Committee Composition
IR Resources
FAQS
Email Alerts
IR & Media Contact
Careers
Intro to Shattuck
Values
Benefits
Join Our Team
Current Openings
Contact
Locations
Contact Us
Follow Us